[Federal Register Volume 84, Number 35 (Thursday, February 21, 2019)]
[Notices]
[Page 5501]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2019-02881]



[[Page 5501]]

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA-392]


Bulk Manufacturer of Controlled Substances Application: Research 
Triangle Institute

ACTION: Notice of application.

-----------------------------------------------------------------------

DATES: Registered bulk manufacturers of the affected basic classes, and 
applicants therefore, may file written comments on or objections to the 
issuance of the proposed registration on or before March 25, 2019. Such 
persons may also file a written request for a hearing on the 
application on or before March 25, 2019.

ADDRESSES: Written comments should be sent to: Drug Enforcement 
Administration, Attention: DEA Federal Register Representative/DPW, 
8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: The Attorney General has delegated his 
authority under the Controlled Substances Act to the Administrator of 
the Drug Enforcement Administration (DEA), 28 CFR 0.100(b). Authority 
to exercise all necessary functions with respect to the promulgation 
and implementation of 21 CFR part 1301, incident to the registration of 
manufacturers, distributors, dispensers, importers, and exporters of 
controlled substances (other than final orders in connection with 
suspension, denial, or revocation of registration) has been redelegated 
to the Assistant Administrator of the DEA Diversion Control Division 
(``Assistant Administrator'') pursuant to section 7 of 28 CFR part 0, 
appendix to subpart R.
    In accordance with 21 CFR 1301.34(a), this is notice that on June 
25, 2018, Research Triangle Institute, 3040 East Cornwallis Road, 
Hermann Bldg., Room 106, Research Triangle Park, North Carolina 27709, 
re-applied to be registered as a bulk manufacturer of small quantities 
of Tetrahydrocannabinols (7370), a basic class of a controlled 
substance listed in schedule I.
    The company will manufacture via synthesis Tetrahydrocannabinols 
(7370), for use by researchers as Active Pharmaceutical Ingredients 
(API) for clinical trials.

    Dated: January 29, 2019.
John J. Martin,
Assistant Administrator.
[FR Doc. 2019-02881 Filed 2-20-19; 8:45 am]
BILLING CODE 4410-09-P